Clovis shares double on positive early data for lung cancer drug
(Reuters) - Clovis Oncology said initial results of an early-stage trial of its experimental lung cancer drug showed a reduction in ...
Read More »Health News
Subscribe to the Health News feed.-
-
BioMarin's cancer drug success prompts launch of pivotal trial
(Reuters) - An experimental cancer drug from BioMarin Pharmaceutical Inc has proven to be effective in treating patients with breast...
Read More » -
Start-up tries tapping market of uninsured dental patients
SAN FRANCISCO (Reuters) - While many healthcare startups are hoping the new healthcare law going into effect next year will help dri...
Read More » -
GSK's breast cancer drug Tykerb fails in gastric cancer study
LONDON (Reuters) - GlaxoSmithKline said on Monday that its breast cancer drug lapatinib in combination with chemotherapy did not imp...
Read More » -
Synta shares fall after lung cancer trial results
CHICAGO (Reuters) - Shares of Synta Pharmaceuticals Corp fell by nearly one-third on Monday morning on disappointing results from it...
Read More » -
Exclusive: EU to fine Lundbeck, others for blocking generic drugs
By Foo Yun Chee BRUSSELS (Reuters) - A European regulator will fine Denmark's Lundbeck and eight other makers of generic drugs for l...
Read More » -
Obama urges greater openness in dealing with mental illness
By Roberta Rampton WASHINGTON (Reuters) - President Barack Obama said on Monday that Americans need to become more open about mental...
Read More » -
Oxford BioMedica pauses some trials after finding potential impurities
(Reuters) - Gene-based biopharmaceutical company Oxford BioMedica said it put some of its trials on hold, after the company detected...
Read More » -
Fittest cities take exercise publicly and personally
By Dorene Internicola NEW YORK (Reuters) - Cities that provide parks, walking trails, playing fields and running tracks are setting ...
Read More » -
Sanofi pulls the plug on two late-stage drugs
PARIS (Reuters) - Sanofi has stopped work on two drugs in late-stage development, iniparib and otamixaban, after tests showed both t...
Read More »